share_log

Roth Capital Initiates Coverage On BioRestorative Therapies With Buy Rating, Announces Price Target of $15

Roth Capital Initiates Coverage On BioRestorative Therapies With Buy Rating, Announces Price Target of $15

羅斯資本以購買評級啟動生物恢復療法的覆蓋範圍,宣布目標價格為 15 美元
Benzinga Real-time News ·  2022/12/07 08:14

Roth Capital analyst Jonathan Aschoff initiates coverage on BioRestorative Therapies (NASDAQ:BRTX) with a Buy rating and announces Price Target of $15.

Roth Capital分析師Jonathan Aschoff以買入評級啟動對生物修復療法(納斯達克:BRTX)的報道,並宣佈目標價為15美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論